



MOVEMBER PROSTATE INITIATIVE



MOVEMBER PROSTATE INITIATIVE



Every year in the Netherlands, about **250,000 men** are screened for prostate cancer and roughly **15,000** receive a diagnosis. Care keeps improving, but there is still room to improve health outcomes and reduce costs. That is why we explored the untapped potential in the Dutch prostate cancer diagnostic pathway.

We modelled and simulated the current standard of care and calculated how much improvement is still possible each year, both financially and clinically. The analysis looked at three stages:

GP screening, hospital diagnostics, and prognostics.

This infographic highlights the opportunities we found, including better detection of significant cancers, fewer unnecessary biopsies, less overtreatment of insignificant cancer, lower overall costs, and stronger patient outcomes. At every stage we included a innovative company that is involved in improving prostate cancer care and how they address this untapped potential.

CURRENT CARE
PATHWAY

VS

OPTIMAL CARE
PATHWAY
(HEADROOM)

GP LEVEL SCREENING



MEN SCREENING AT
GP IN THE
NETHERLANDS
(YEARLY)
N = 250.000

FINDING MORE
AGGRESSIVE CANCER



4.641
More significant
cancers detected

AVOID
OVERTREATMENT



23.758
Reduced overdiagnosis
(of which 7.839 insignificant
cancers)


*"With our reflex blood
test **Proclarix**®, physicians can
more accurately identify the risk
of clinically significant prostate
cancer in men with an elevated
PSA of 2-10 ng/mL, while
protecting 50% of false-positive
tested men from worries and
follow-on costs"*

Dr. Beat Rheiner, PhD, CEO at
Proteomedix

 **Proteomedix**

HEALTH SYSTEM
SAVINGS

€64.2
MILLION



HEALTHY LIFE-
YEARS GAIN



2.468
QALY



DIAGNOSTICS AT HOSPITAL



MEN REFERRED TO
HOSPITAL
(YEARLY)
N = 50.000

FINDING MORE
AGGRESSIVE CANCER



1.336
More significant
cancers detected

PREVENTED
BIOPIES



21.492 (-59%)
Unnecessary
biopsies prevented

*"Our AI-powered **QP-Prostate** solution empowers clinicians to detect clinically significant prostate cancer earlier while reducing unnecessary biopsies. This means better outcomes for patients and a more efficient healthcare system."*


Javier Pizcueta Pastor, Director
of Business Development -
EMEA & LATAM at Quibim



Quibim

HEALTH SYSTEM
SAVINGS

€26.5
MILLION ↓



HEALTHY LIFE-
YEARS GAIN



1.537
QALY ↑

PROGNOSTICS



MEN WITH STAGE
1 – 3 PROSTATE
CANCER
(YEARLY)
N = 11.000

PREVENT
OVERTREATMENT



2.640
Less overtreatment
of prostate cancer

METASTATIC
CANCER



112
Metastatic cancers
prevented




*“With the **Prostatype Genomic Classifier** now available across the United States and the European Union, we are proud to offer clinicians this next-generation prognostic tool that enhances decision-making in prostate cancer care. Prostatype provides objective meaningful biological insight that supports individualized treatment planning and helps patients and physicians choose the most appropriate course of care with confidence.”*

Steve Gaal, President at
Prostatype Genomics Inc.



HEALTH SYSTEM
SAVINGS

€10.75
MILLION



HEALTHY LIFE-
YEARS GAIN



4.784
QALY



DISCLAIMER

The model used for this headroom analysis is the Medip Prostate Dx Application 1.1.0 from the Health Economic Software Platform developed by Medip Analytics, Nijmegen, The Netherlands. Model and input used in the referenced publication for the Dutch population (<https://link.springer.com/article/10.1007/s00259-025-07190-6>).

The Medip Prostate Dx Application is a dynamic software application that connects to an individual-level patient simulation model of the prostate cancer pathway. Within the software, the comparator (standard of care) and the position and characteristics of the strategy under evaluation can be adjusted.

The results shown here are separate outputs and cannot be combined, because outcomes from earlier steps in the diagnostic pathway affect later stages. No rights can be derived from the results of this analysis.

For questions about the model, visit www.medipanalytics.com or contact info@medipanalytics.com.